Aimovig Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Aimovig market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as the rising prevalence of migraine disorders, advancements in CGRP (calcitonin gene-related peptide) research, increasing demand for targeted migraine treatments, growing recognition of chronic migraines as a neurological condition, supportive regulatory approvals for migraine therapies, expanding healthcare access and infrastructure, and increased investment in biotechnology for innovative treatments.

In the forecast period, growth is expected to be driven by the increasing prevalence of chronic migraines, continued advancements in CGRP inhibitors, and the growing adoption of Aimovig as a first-line treatment for migraine prevention. Additionally, expanding clinical evidence supporting Aimovig's efficacy, the rising demand for non-daily migraine treatments, increased healthcare investments in neurological disorders, and expanding insurance coverage for migraine therapies will contribute to growth. Major trends during this period include the growing adoption of CGRP inhibitors, development of more convenient delivery methods like self-administered injections, integration of advanced monitoring technologies for personalized treatment, rising collaborations between biotech firms and healthcare providers, a growing focus on personalized migraine therapies, and market expansion into emerging regions with high unmet medical needs.

The increasing incidence of migraine disorders is expected to drive the growth of the aimovig market. Migraines are a complex neurological condition characterized by recurring headaches and various other symptoms such as nausea and sensitivity to light. The rising prevalence of migraines can be attributed to factors such as lifestyle changes, heightened stress levels, hormonal fluctuations (particularly in women), genetic predispositions, and greater awareness and diagnosis. Aimovig, the first FDA-approved CGRP receptor blocker, offers a preventive treatment for migraine patients, addressing an unmet need by providing a targeted solution. Aimovig's AI-driven migraine management platform tracks, analyzes, and predicts migraine triggers, helping patients reduce the frequency and intensity of attacks. According to the House of Commons Library, approximately 10 million people in the UK live with migraines, highlighting the growing need for effective treatments like aimovig, which is driving the market's growth.

The rise in healthcare spending is propelling the growth of the aimovig market. Increased healthcare spending, driven by factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases, supports investments in innovative treatments. This includes funding for Aimovig and expanding patient access through insurance coverage. The increase in healthcare expenditures also supports ongoing research and development for better therapeutic outcomes and enhances the adoption of migraine prevention therapies. For example, in May 2024, the UK's healthcare spending grew by 5.6%, with total healthcare expenditure amounting to approximately $317.63 billion (£292 billion) in 2023. This increase in healthcare spending is boosting the demand for treatments like aimovig.

The rise of personalized medicine is expected to boost the growth of the Aimovig market. Personalized medicine tailors treatment strategies to individual patients based on their genetic makeup, lifestyle, and other personal factors, leading to more effective outcomes and fewer side effects. Advancements in genomic technologies and the growing availability of precision diagnostic tools have spurred the rise of personalized medicine. Aimovig, as a monoclonal antibody that targets the calcitonin gene-related peptide receptor, helps personalize treatment for chronic migraine patients, optimizing therapeutic outcomes based on patient-specific factors like treatment history and tolerability. According to the Personalized Medicine Coalition, in 2022, 34% of new FDA-approved drugs were personalized medicines, illustrating the growing trend in this area, which supports the demand for personalized treatments like aimovig.

key players in the aimovig market are Novartis AG, Amgen Inc.

North America was the largest region in the aimovig market in 2024. The regions covered in aimovig report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the aimovig market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Aimovig is a therapy designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor. It works by blocking CGRP activity, a protein involved in triggering migraines, thus reducing their frequency and severity.

The primary clinical indication for Aimovig is migraine prevention, along with treatment for cluster headaches and other headache disorders. A migraine is a type of primary headache disorder, characterized by recurrent, often intense headaches that are typically unilateral, though they may affect both sides. Migraines are often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light, sound, or smells. Aimovig is distributed through various channels, including hospitals, clinics, retail, and specialty pharmacies, and is used by different end-users, including adults and geriatric patients.

The aimovig market research report is one of a series of new reports that provides aimovig market statistics, including aimovig industry global market size, regional shares, competitors with a aimovig market share, detailed aimovig market segments, market trends, and opportunities, and any further data you may need to thrive in the aimovig industry. This aimovig market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aimovig market consists of sales of monoclonal antibody-based therapies specifically developed to prevent migraines by inhibiting CGRP receptor activity. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.